Monte Rosa Therapeutics (GLUE) Total Liabilities (2020 - 2026)

Monte Rosa Therapeutics' Total Liabilities history runs 7 years deep, the most recent figure standing at $214.5 million for Q1 2026.

• In Q1 2026, Total Liabilities rose 81.73% year-over-year to $214.5 million; the TTM figure through Mar 2026 stood at $214.5 million (up 81.73% YoY), while the FY2025 annual figure was $215.6 million, changed 0.09% from the prior year.
• Total Liabilities was $214.5 million for Q1 2026 at Monte Rosa Therapeutics, down from $215.6 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $215.8 million in Q4 2024 to a low of $20.1 million in Q1 2022.
• Historically, Total Liabilities has averaged $115.0 million across 5 years, with a median of $109.6 million in 2024.
• Biggest YoY gain for Total Liabilities was 413.79% in 2022; the steepest drop was 66.79% in 2022.
• A 5-year view of Total Liabilities shows it stood at $71.0 million in 2022, then surged by 75.42% to $124.5 million in 2023, then surged by 73.32% to $215.8 million in 2024, then decreased by 0.09% to $215.6 million in 2025, then slipped by 0.51% to $214.5 million in 2026.
• The last three Total Liabilities figures came in at $214.5 million (Q1 2026), $215.6 million (Q4 2025), and $214.0 million (Q3 2025), per Business Quant data.